The value of animal models for drug development in multiple sclerosis.
The rodent model for multiple sclerosis, experimental allergic (autoimmune) encephalomyelitis (EAE), has been used to dissect molecular mechanisms of the autoimmune inflammatory response, and hence to devise and test new therapies for multiple sclerosis. Clearly, artificial immunization against myel...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797073551585443840 |
|---|---|
| author | Friese, M Montalban, X Willcox, N Bell, J Martin, R Fugger, L |
| author_facet | Friese, M Montalban, X Willcox, N Bell, J Martin, R Fugger, L |
| author_sort | Friese, M |
| collection | OXFORD |
| description | The rodent model for multiple sclerosis, experimental allergic (autoimmune) encephalomyelitis (EAE), has been used to dissect molecular mechanisms of the autoimmune inflammatory response, and hence to devise and test new therapies for multiple sclerosis. Clearly, artificial immunization against myelin may not necessarily reproduce all the pathogenetic mechanisms operating in the human disease, but most therapies tested in multiple sclerosis patients are nevertheless based on concepts derived from studies in EAE. Unfortunately, several treatments, though successful in pre-clinical EAE trials, were either less effective in patients, worsened disease or caused unexpected, severe adverse events, as we review here. These discrepancies must, at least in part, be due to genetic and environmental differences, but the precise underlying reasons are not yet clear. Our understanding of EAE pathogenesis is still incomplete and so, therefore, are any implications for drug development in these models. Here, we suggest some potential explanations based on new thinking about key pathogenic concepts and differences that may limit extrapolation from EAE to multiple sclerosis. To try to circumvent these rodent-human dissimilarities more systematically, we propose that pre-clinical trials should be started in humanized mouse models. |
| first_indexed | 2024-03-06T23:23:47Z |
| format | Journal article |
| id | oxford-uuid:69ad6635-dbbc-4628-b656-927764fa1bd1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:23:47Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:69ad6635-dbbc-4628-b656-927764fa1bd12022-03-26T18:52:32ZThe value of animal models for drug development in multiple sclerosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69ad6635-dbbc-4628-b656-927764fa1bd1EnglishSymplectic Elements at Oxford2006Friese, MMontalban, XWillcox, NBell, JMartin, RFugger, LThe rodent model for multiple sclerosis, experimental allergic (autoimmune) encephalomyelitis (EAE), has been used to dissect molecular mechanisms of the autoimmune inflammatory response, and hence to devise and test new therapies for multiple sclerosis. Clearly, artificial immunization against myelin may not necessarily reproduce all the pathogenetic mechanisms operating in the human disease, but most therapies tested in multiple sclerosis patients are nevertheless based on concepts derived from studies in EAE. Unfortunately, several treatments, though successful in pre-clinical EAE trials, were either less effective in patients, worsened disease or caused unexpected, severe adverse events, as we review here. These discrepancies must, at least in part, be due to genetic and environmental differences, but the precise underlying reasons are not yet clear. Our understanding of EAE pathogenesis is still incomplete and so, therefore, are any implications for drug development in these models. Here, we suggest some potential explanations based on new thinking about key pathogenic concepts and differences that may limit extrapolation from EAE to multiple sclerosis. To try to circumvent these rodent-human dissimilarities more systematically, we propose that pre-clinical trials should be started in humanized mouse models. |
| spellingShingle | Friese, M Montalban, X Willcox, N Bell, J Martin, R Fugger, L The value of animal models for drug development in multiple sclerosis. |
| title | The value of animal models for drug development in multiple sclerosis. |
| title_full | The value of animal models for drug development in multiple sclerosis. |
| title_fullStr | The value of animal models for drug development in multiple sclerosis. |
| title_full_unstemmed | The value of animal models for drug development in multiple sclerosis. |
| title_short | The value of animal models for drug development in multiple sclerosis. |
| title_sort | value of animal models for drug development in multiple sclerosis |
| work_keys_str_mv | AT friesem thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT montalbanx thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT willcoxn thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT bellj thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT martinr thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT fuggerl thevalueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT friesem valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT montalbanx valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT willcoxn valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT bellj valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT martinr valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis AT fuggerl valueofanimalmodelsfordrugdevelopmentinmultiplesclerosis |